NEW YORK (GenomeWeb News) — XDx will in-license IP from the University of Minnesota that will enable the company to use gene expression technology to assess the status of systemic lupus erythematosus in patients, it said last week.

 

XDx also said it has entered a separate agreement with UM and the Feinstein Institute for Medical Research in New York that gives the company access to SLE patient samples taken from an NIH-funded study of biomarkers for autoimmune diseases.